Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CellaVision AB ( (SE:CEVI) ) has shared an update.
CellaVision reported a solid fourth quarter of 2025, with net sales up 5.6% to SEK 197 million and organic growth of 12.2%, driven primarily by a 50% sales surge in the Americas and steady gains in EMEA, while APAC declined on tough comparisons. EBITDA rose to SEK 65 million, maintaining a 33% margin, cash flow from operations strengthened to SEK 51 million, and the board proposed a higher dividend of SEK 2.75 per share, underscoring confidence in the company’s financial position. The group advanced its strategic agenda by securing CE marking for its new Bone Marrow Aspirate Application, validating an upgraded hematology software platform for rollout in 2026, and progressing development of next‑generation microscopy based on Fourier Ptychographic Microscopy, moves that are expected to reinforce its leadership in digital hematology and open adjacent market opportunities despite regional demand volatility.
The most recent analyst rating on (SE:CEVI) stock is a Buy with a SEK156.00 price target. To see the full list of analyst forecasts on CellaVision AB stock, see the SE:CEVI Stock Forecast page.
More about CellaVision AB
CellaVision AB is a medical technology company specializing in digital cell morphology solutions for hematology laboratories. Its portfolio includes automated analyzers, software and reagents that digitize and standardize blood and bone marrow microscopy, with a strong market focus on larger integrated health networks and clinical labs across the Americas, EMEA and APAC.
Average Trading Volume: 30,092
Technical Sentiment Signal: Sell
Current Market Cap: SEK3.36B
Find detailed analytics on CEVI stock on TipRanks’ Stock Analysis page.